The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Jun. 24, 2021
Applicant:
Chemocentryx, Inc., San Carlos, CA (US);
Inventors:
Junfa Fan, Palo Alto, CA (US);
Jaroslaw Kalisiak, Mountain View, CA (US);
Rebecca M. Lui, Mountain View, CA (US);
Venkat Reddy Mali, Cupertino, CA (US);
Jeffrey P. McMahon, San Francisco, CA (US);
Jay P. Powers, Pacifica, CA (US);
Hiroko Tanaka, Mountain View, CA (US);
Yibin Zeng, Foster City, CA (US);
Penglie Zhang, Foster City, CA (US);
Assignee:
CHEMOCENTRYX, INC., Thousand Oaks, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/35 (2006.01); A61K 31/453 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/536 (2006.01); A61K 31/538 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07D 309/24 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/453 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/536 (2013.01); A61K 31/538 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01);
Abstract
Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.